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While the spread of Salmonella enterica serotype Kentucky resistant to ciprofloxacin
across Africa and the Middle-East has been described recently, the presence of this
strain in humans, food, various animal species (livestock, pets, and wildlife) and in
environment is suspected in other countries of different continents. Here, we report
results of an in-depth molecular epidemiological study on a global human and non-human
collection of S. Kentucky (n = 70). We performed XbaI-pulsed field gel electrophoresis and
multilocus sequence typing, assessed mutations in the quinolone resistance-determining
regions, detected β-lactam resistance mechanisms, and screened the presence of the
Salmonella genomic island 1 (SGI1). In this study, we highlight the rapid and extensive
worldwide dissemination of the ciprofloxacin-resistant S. Kentucky ST198-X1-SGI1 strain
since the mid-2000s in an increasingly large number of contaminated sources, including
the environment. This strain has accumulated an increasing number of chromosomal
and plasmid resistance determinants and has been identified in the Indian subcontinent,
Southeast Asia and Europe since 2010. The second substitution at position 87 in GyrA
(replacing the amino acid Asp) appeared helpful for epidemiological studies to track the
origin of contamination. This global study provides evidence leading to the conclusion that
high-level resistance to ciprofloxacin in S. Kentucky is a simple microbiological trait that
facilitates the identification of the epidemic clone of interest, ST198-X1-SGI1. Taking this
into account is essential in order to detect and monitor it easily and to take rapid measures
in livestock to ensure control of this infection.
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INTRODUCTION
Despite the substantial progress made in preventing foodborne
diseases, new pathogens have emerged, some of which have spread
worldwide decade after decade (Tauxe, 1997). These pathogens
include strains of multi-drug resistant (MDR) Salmonella (Arlet
et al., 2006; Walsh and Fanning, 2008). Their treatment in
both animals and humans has become more difficult and the
number of reports of foodborne infections and outbreaks of
MDR Salmonella has increased (Angulo et al., 2000; Mølbak,
2005). The global spread of an MDR Salmonella enterica serotype
Typhimurium phage type DT104 in animals and humans since
the 1990s (Threlfall, 2000; Mather et al., 2013) is a good example.
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While the spread of DT104 may have been facilitated by the use
of antimicrobials, the national and international trade of infected
animals is thought to have played a major role in its spread across
borders (Ribot et al., 2002; Weill et al., 2006a).
More recently, an emerging S. Kentucky strain has been
described (Weill et al., 2006b; Le Hello et al., 2011) and
belonged to the ST198-X1 subtype. It has accumulated various
chromosomal resistance determinants since the mid-1990s with
the integration of the Salmonella genomic island 1 (SGI1), a
43-kilobase genomic island initially described in DT104 (Boyd
et al., 2001), encoding resistance to multiple antimicrobials
including amoxicillin, gentamicin, and sulfonamides (Doublet
et al., 2008), followed by cumulative mutations in the gyrA
and parC genes, leading to resistance to nalidixic acid and then
to ciprofloxacin in 2002 (S. Kentucky CIP-R). This popula-
tion was mostly detected in Egypt before 2005, but has now
rapidly spread throughout Africa and the Middle East (Le Hello
et al., 2011). Another matter of concern is the expanding live-
stock reservoir of this S. Kentucky CIP-R strain. It was initially
identified in autochthonous poultry but was then found in var-
ious animals and foods (contaminated spices in France and
the United States of America (US), turkey flocks in Germany
and Poland, wild animals, etc) (Le Hello et al., 2011; Beutlich
et al., 2012; Münch et al., 2012; Wasyl and Hoszowski, 2012).
Several isolates give rise to considerable concern, as they have
become producers of various carbapenemases and/or cephamyci-
nase and/or extended spectrum β-lactamases (ESBL) (Le Hello
et al., 2013).
Since these studies, several reports have mentioned
S. Kentucky CIP-R isolates that have been identified from
different sources (animals, food, the environment and humans)
and geographic locations, in particular in several new countries
in the Indian sub-continent and Southeast Asia. The purpose
of this study was to examine whether the S. Kentucky strains
isolated around the world from different ecosystems belong to
this expanding ST198-X1-SGI1 strain.
MATERIALS AND METHODS
COLLECTION OF STRAINS
Following the publication of the first studies on S. Kentucky
ST198-X1-SGI1 CIP-R surveillance (Weill et al., 2006b; Le Hello
et al., 2011, 2013), public health agencies in several different
regions have notified the same isolation of S. Kentucky CIP-
R in their animal flocks, in the environment, in food and in
humans (traveler-related or domestic). We studied 70 S. Kentucky
strains from the following participating countries: 41 strains col-
lected from the French National Reference Center for Salmonella
(FNRC-Salm), 11 from the French Food Safety Agency Salmonella
network (ANSES Laboratory for Food Safety, Maisons-Alfort,
France), six from Denmark (five from the Veterinary Clinical
Microbiology Section, Department of Veterinary Disease Biology,
University of Copenhagen and one from the Technical University
of Denmark, DTU), five from Germany (three from the National
Reference Laboratory for Salmonella, Federal Institute for Risk
Assessment, BfR, and two from the German National Reference
Center for Salmonellae and other Enterics, RKI), three from the
NSW Enteric Reference Laboratory, ICPMR, Westmead Hospital,
Sydney (Australia), two from the National Veterinary Research
Institute (Poland) and one from the Institut Pasteur of Morocco,
and the reference strain 98K (Edwards, 1938) from the WHO
Collaborating Center for Reference and Research on Salmonella,
Paris, France.
The global collection, presented inTable 1, gathers S. Kentucky
isolates from around the world (four continents, 28 countries)
covering a long time-span (including preantibiotic era isolates,
from 1937 to 2013), various livestock species (swine, turkey,
layer, and broiler poultry farms), humans, food (soya bean, meat,
seafood, and spices), wild and domestic animals (reptiles, horses,
camels, birds, dogs) and the environment (compost and rivers).
MICROBIOLOGICAL INVESTIGATIONS
Serotyping was performed on the basis of the White-Kauffmann-
Le Minor scheme (Grimont and Weill, 2007). We carried out
antimicrobial susceptibility testing (AST) on all S. Kentucky iso-
lates with the disk diffusion method, for a panel of 32 antimicro-
bial drugs (Bio-Rad, Marnes-La-Coquette, France). Using Etests
(bioMérieux, Marcy l’′Etoile, France), we determined the min-
imum inhibitory concentration (MIC) of ciprofloxacin, as pre-
viously described (Le Hello et al., 2013). The results were then
interpreted using the breakpoints of the Antibiogram Committee
of the French Society for Microbiology (CA-SFM) which imple-
ments the EUCAST breakpoints. Resistance to ciprofloxacin is
defined as having an MIC of more than 1 mg/L and being suscep-
tible at an MIC of 0.5 mg/L or less, irrespective of isolate source
(i.e., intestinal or extraintestinal).
For molecular typing, we performed multilocus sequence typ-
ing (MLST) on all S. Kentucky isolates and PulseNet standard
pulsed-field gel electrophoresis (PFGE) ofXbaI-digested chromo-
somal DNA on a selection of isolates (n = 50) (Le Hello et al.,
2011; Achtman et al., 2012).
To determine the resistance mechanisms, we assessed the
presence of β-lactam resistance genes (blaTEM , blaSHV , blaPSE,
blaOXA−1group, blaCMY , blaCTX−M , blaOXA−48, blaVIM , blaNDM ,
and blaKPC), plasmid-mediated quinolone resistance genes
(known PMQR genes, qnrA, qnrB, qnrS, qnrD, aac(6)′-Ib-cr,
qepA and the recent oqxA and oqxB), macrolide resistance genes
(mphA) and Salmonella genomic island1 (SGI1) by PCR, as
described previously (Le Hello et al., 2013; Li et al., 2013).
Variants SGI1-K, P, and Q and J were differentiated in some
strains (n = 28) by selected primers, as described in Table 2 and
also described previously (Doublet et al., 2008; Le Hello et al.,
2012).
The quinolone resistance-determining region (QRDR) of
gyrA, gyrB, parC, and parE (encoding subunits of the DNA gyrase
and the topoisomerase IV) was sequenced in all S. Kentucky
strains as described previously (Le Hello et al., 2013). The
nucleotide and deduced amino acid sequences were analyzed and
compared with sequences available from the National Center for
Biotechnology Information.
RESULTS
The Table 1 presents the characteristics of serotype Kentucky iso-
lates and summarizes the results of antimicrobial resistance and
genomic typing.
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Table 2 | PCR set (SGI1- Ks, -Ps, and -Qs).
PCR No. Primer Nucleotide sequence (5’-3’) Tm(◦C) Size (bp) Remark
13 sulTER AAGGATTTCCTGACCCTG 59 2040 + for SGI1-Ks
RvTn501 ATGGATGTGGTGGCTGAAGG 67.2
A FwS026 CGGTTTTGAATAAGAAGGCA 61.5 Variable + for SGI1-Ps
OT4 CCAATGCTTAATCAGTGAGG 59.7
23 OT3 ATGAGTATTCAACATTTCCG 56.5 2192 + for SGI1-Ps and – for SGI1-Qs
RvS044c GTATTGTCGTCGGGATGATT 61.2
C FwS026 CGGTTTTGAATAAGAAGGCA 61.5 Variable (∼1500–3000) + for SGI1-Qs
RvS044c GTATTGTCGTCGGGATGATT 61.2
MOLECULAR TYPING
All but one of the 70 S. Kentucky isolates belonged to the e-burst
group 56: ST198 and two single locus variants (SLV), ST727 and
ST1680. The remaining isolate belonged to a new ST, ST1679,
sharing only three loci out of seven (this isolate was susceptible to
quinolones and belonged to an X3 PFGE type). We distinguished
diverse PFGE types among the ST198 and SLV isolates. The major
one, X1 and its many variants (X1a–X1x), representing almost
90% of the ST198 isolates (n = 44), has been associated with
strains isolated over the last 50 years, whereas X2 (n = 2/N = 50)
has been linked to isolates from Asia isolated before the 2000s and
several other patterns for older strains isolated before the 1980s
(X4 for the reference strain 98K and strain 5–76 isolated from soya
bean, and X18 for a Vietnamese strain, isolated in 1937, 1976, and
1966, respectively). Most common representative PFGE subtypes
are shown in Figure 1.
The SGI1-K variants were firstly identified in Kentucky ST198
isolates from Egypt in 1996. Then, the SGI1-Ks and its deriva-
tive variants -Ps or -Qs were present in all the ST198 (or its SLV)
isolates. As shown here, all the SGI1 variants were independently
distributed between periods, countries and sources (Table 1).
ANTIMICROBIAL SUSCEPTIBILITY TESTING AND RESISTANCE GENES
Among the S. Kentucky isolates studied, increased resistance
to fluoroquinolones has been observed since the isolation of
the first ciprofloxacin-resistant isolate in 2002. As shown in
Table 1 ciprofloxacin MICs seem to increase over time, from
0.008mg/L to 0.125mg/L during the 1990s, 4mg/L to 12mg/L
between 2002 and 2006 and since 2007 with the emergence
of highly ciprofloxacin resistant strains (16 to >32mg/L).
Apart from quinolone resistance, additional resistance was
observed in some S. Kentucky CIP-R isolates (Table 1). The
most prevalent drug resistance patterns were R1 (n = 25, 46%),
which included resistance to amoxicillin, streptomycin, specti-
nomycin, gentamicin, sulfamethoxazole, and tetracycline; R2
(n = 8, 15%), which included resistance to amoxicillin; and
R3 (n = 4, 7%), which included resistance only to nalidixic
acid and ciprofloxacin. Before 2002, these resistance patterns
were also described with decreased susceptibility to ciprofloxacin
(CIP-DS; MIC, 0.125mg/L). These patterns and other less fre-
quent ones were all associated with the presence of SGI1-Ks
(for R1) and -Ps (for R2), both carrying the blaTEM gene,
and -Qs (for R3 which do not carry any drug resistance
genes).
FIGURE 1 | Representatives of XbaI-PFGE profiles obtained among S.
enterica serotype Kentucky isolates from humans and nonhumans
during the period 1937–2013.
More recently, additional resistance to third generation
cephalosporins (C3G) and/or carbapenems was observed in
CIP-R S. Kentucky X1-ST198-SGI1 isolates. These isolates
contained the cephamycinase blaCMY−2 (n = 3), the ESBLs
blaCTX−M−1(n = 1) and blaCTX−M−15(n = 1), and the carbapen-
emases blaVIM−2(n = 1) and blaOXA−48(n = 2). High-level resis-
tance to azithromycin (32mg/L to 128mg/L) was found in four
of them which carried the phosphotransferasemphA gene known
to inactivate macrolide antimicrobial drugs.
In addition to the ST198-X1 SGI1-Ks, -Ps, and -Qs isolates,
we observed other drug-resistant S. Kentucky ST198 populations
in our collection. Initially, we identified ST198-X2, which car-
ried SGI-Js and was isolated in Asia before the 2000s (see Le
Hello et al., 2012); secondly, we identified here for the first time
a putative SGI1-B variant carrying S. Kentucky ST198 isolate (no.
2010/07297) which contains a blaPSE−1 gene found occasionally
in other serotypes such as Typhimurium DT104 and Paratyphi B
d-tartrate fermenting (Boyd et al., 2002; Weill et al., 2005). Lastly,
an SGI1 free isolate susceptible to nalidixic acid and producing
the CMY-2 cephamycinase was acquired in Mali in 2011 (no.
2011/01801).
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TEMPORAL AND GEOGRAPHIC DISTRIBUTION OF S. KENTUCKY
ISOLATES WITH QRDR MUTATIONS
As shown in Table 1, ciprofloxacin resistance in all the 54 CIP-R
S. Kentucky isolates was related to GyrA and ParC substitutions
(Table 1). All contained double substitutions in GyrA (at codons
Ser83 and Asp87) and a single ParC substitution (Ser80 encoding
an isoleucine residue). None of the isolates contained GyrB or
ParE modifications. In GyrA, all the isolates contained phenylala-
nine at codon Ser83, whereas mutations in codon Asp87 resulted
in different substitutions to asparagine (Asn), tyrosine (Tyr),
or glycine (Gly) residues depending on the geographic origin
of the isolates (Figure 2). All the Egyptian isolates presented
three possible mutations in codon Asp87 (n = 6), whereas the
isolates from North Africa (Morocco, Algeria, Tunisia, Libya)
had a modification that resulted in Asp87Asn (n = 7). An
exception was the VIM-2 producing Kentucky 2010/01922
isolate from Morocco which had Asp87Tyr. Those from the
Middle East (Iraq, United Arab Emirates, Kuwait, Turkey, and
Iran) presented both Asp87Gly and Asp87Asn, apart from two
nonhuman Ethiopian isolates and one Sudanese human isolate
in 2005 that had an Asp87Gly substitution; those from East
Africa, India and Bangladesh had an Asp87Tyr modification
(n = 12). Apart from the two strains from the Ivory Coast which
presented Asp87Tyr, those from West Africa presented Asp87Gly
(n = 3). All three isolates from Southeast Asia (Cambodia,
Indonesia and Vietnam) had an Asp87Asn amino acid
change.
Isolates from food, animal feed and the environment iso-
lated in Europe presented an intermediate situation with isolates
mostly having an Asp87Tyr residue in Germany and Poland and
an Asp87Asn residue in France.
No PMQR genes, such as qnr, aac(6′)-Ib-cr, qepA and oqxAB
were detected in S. Kentucky CIP-R isolates of this study.
NONHUMAN SOURCES OF THE S. KENTUCKY ST198-X1-SGI1 STRAIN
The nonhuman isolates of S. Kentucky ST198-X1-SGI1 have
mainly been found in poultry farms (chicken, layer and turkey,
n = 14) since its first description in a chicken from Ethiopia in
2006 (Le Hello et al., 2011). This strain has further been described
in poultry flocks in East, West and North Africa, the Indian sub-
continent and Europe. It has also been described in food products
(seafood, meat, or spice), domestic animals (dog, horse, camel, or
pet reptiles) and wild animals (houbara or reptiles) and various
environments (river or compost) (see Table 1).
DISCUSSION
By gathering and studying this global collection, we confirmed
that one strain has disseminated throughout the developing coun-
tries in both human and nonhuman sources. Strain ST198-X1
displays high-level resistance to ciprofloxacin and harbors SGI1-
Ks or its derivative variants -Ps or -Qs. The high-diversity of
antibiotic resistance patterns could be related to genetic rear-
rangements mediated by various insertion sequences (in partic-
ular IS26) and transposons in SGI1-Ks, -Ps, and -Qs (Doublet
et al., 2008). In parallel, contrary to the relatively few PFGE
patterns associated with S. Typhimurium DT104, S. Kentucky
ST198 displayed high-diversity in X1 subtypes, suggesting fre-
quent events of genomic rearrangements present in SGI1 or the
acquisition/loss of various plasmids. Several other ST198 strains
belonging to other PFGE subtypes and/or containing different
antibiotic resistance mechanisms have been isolated sporadically
or have no longer been isolated since the 2000s (Le Hello et al.,
FIGURE 2 | Geographical distribution in the eastern hemisphere of the different substitutions at codon 87 of GyrA to asparagine (Asn), tyrosine (Tyr),
or glycine (Gly) in S. enterica serotype Kentucky resistant to ciprofloxacin of the present collection. H, Human isolates; V, nonhuman isolates.
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2012). The odyssey of the S. Kentucky ST198-X1 isolate has lasted
since it was found in Egypt in the mid-1990s. It has since then
accumulated various chromosomal resistance determinants, with
the integration of SGI1 (encoding resistance to multiple antimi-
crobial drugs), followed by cumulative mutations in the gyrA and
parC genes, leading to resistance to nalidixic acid, and then to
ciprofloxacin in 2002. Since 2002, this strain has spread rapidly
throughout Africa and theMiddle East (Le Hello et al., 2011) and,
in 2009, it was identified in India in travelers and in Bangladesh
in poultry flocks (Barua et al., 2012, 2013). Furthermore, the
first description of SGI1 variant K was identified in a Salmonella
serotype Kentucky strain isolated in 2001 from spices imported
into Australia from India (Levings et al., 2007). Since 2011, a pat-
tern of propagation across Asia is also suggested by the recent
recovery of ciprofloxacin-resistant S. Kentucky isolates from stool
samples of patients in France and Australia with a history of
recent travel to Vietnam, Cambodia and Indonesia. This global
collection also makes it possible to confirm the recent increase
of S. Kentucky ST198-X1-SGI1 CIP-R clinical strains that have
acquired additional genes, making them resistant to extended
spectrum cephalosporins and/or carbapenems, in particular in
the Mediterranean basin (Collard et al., 2007; Le Hello et al.,
2013). High-level resistance to azithromycin due to the acqui-
sition of the mphA gene among these isolates is of concern as
this antimicrobial agent is presented as a good alternative treat-
ment for severe Salmonella infections (Hill and Beeching, 2010)
and it completes the variety of enteric bacteria already described
producing this phosphotransferase (Boumghar-Bourtchai et al.,
2008). Last but not least, as shown in this study, ciprofloxacin
MIC has increased decade after decade in S. Kentucky isolates.
The recent increase in MIC is not due to additional mutations
in QRDR, nor to the presence of PMQR. However, the increase
could be due to the overexpression of an efflux system such as
AcrAB-TolC (Baucheron et al., 2013).
Another matter of concern is the expanding livestock reservoir
of this S. Kentucky ST198-X1-SGI1 CIP-R strain, initially iden-
tified in African autochthonous poultry but subsequently found
in various animals and food (Le Hello et al., 2011; Barua et al.,
2012, 2013; Beutlich et al., 2012; Münch et al., 2012; Wasyl and
Hoszowski, 2012). Poultry flocks have contributed to the global
dissemination of this clone in developing countries since 2005.
Hence this strain was isolated in Ethiopia in 2006 (chicken),
Nigeria (chicken), and Morocco (turkey) in 2008 (Le Hello et al.,
2011), in Togo (chicken) in 2009, and from layers in 2009, from
broilers in 2010 in Bangladesh (Barua et al., 2012, 2013), and in
developed countries since 2010 (Poland, Wasyl and Hoszowski,
2012; Germany, Beutlich et al., 2012; and France, Guillon et al.,
2013). Interestingly, the S. Kentucky ST198-X1-SGI1 CIP-R iden-
tified in Europe was exclusively associated with turkeys. An inves-
tigation following the epidemics in Poland (Wasyl andHoszowski,
2012) has established that at least one of the infected flocks was
hatched from eggs imported from the Middle East. The diversity
of nonhuman sources described in this study is another reason of
concern. In particular, the description of S. Kentucky ST198-X1-
SGI1 CIP-R in the environment (rivers and compost) and ani-
mals such as reptiles, indicates its potential long-term presence,
suggesting its capacity to produce biofilm, as was previously
identified in Tunisian isolates (Turki et al., 2012). This intrinsic
characteristic could possibly facilitate secondary contaminations
and persistence into a novel host/source but this remains to be
investigated.
Regarding its recent establishment in Bangladesh (18% of 500
farms were S. Kentucky positive during the period 2009–2010),
we do not have any information on how S. Kentucky ST198-
X1-SGI1 CIP-R was introduced in poultry, although locally pro-
duced fish meal used as a protein source has been associated
with the presence of Salmonella in flocks (Barua et al., 2012,
2013). Small poultry farmers purchase this raw ingredient from
the local market to produce low-cost feed by mixing it with
other ingredients. Meat and bone meal imported from different
countries are also used for preparing poultry and fish feed as
a source of protein. Regarding broiler chicks, they are supplied
from commercial breeding farms. Further investigations are nec-
essary to obtain information on locally produced poultry feed.
The microbiological characteristics of Kentucky ST198-X1-SGI1
CIP-R isolated from poultry farms in Bangladesh indicated that
the amino acid substitution in codon 87 of GyrA was exclu-
sively a tyrosine residue like that found in Kentucky for India,
East Africa, Egypt and in some Middle East countries. We do
not know whether humans play any role in the introduction
of this strain in various flocks. Regarding this, it is notewor-
thy that several million emigrants from Bangladesh work in the
Middle East. The human role in the contamination of livestock by
S. Kentucky ST198-X1-SGI1CIP-R has been pinpointed recently
in local turkey flocks in France. The epidemiological investigation
performed highlighted the introduction of this strain follow-
ing the return of farmers from Morocco, a country where this
strain is endemic, and suffering from diarrhea (Guillon et al.,
2013). This hypothesis may be further reinforced as this isolate
(12CEB4452) presented GyrA Asp87Asn substitution which is
clearly associated with the North African S. Kentucky ST198-X1-
SGI1 CIP-R, while isolate 13CEB2160, found in turkey meat sold
in France but imported from Poland, presented tyrosine substitu-
tion, a characteristic described more frequently in Polish turkey
flocks.
In the era of globalized food supply, livestock, and inter-
national human travel, the ciprofloxacin-resistant S. Kentucky
ST198-X1-SGI1 strain is not restricted to one country, ren-
dering measures to subject livestock to controls more difficult.
National and international health, food, and agricultural author-
ities should include it among the strains targeted in national
programs to control Salmonella spp in poultry. Based on differ-
ent studies, including this one, the S. Kentucky ST198-X1-SGI1
epidemic clone of interest can nowadays easily be identified by
simple serotyping (Kentucky) and by testing its susceptibility
in vitro to ciprofloxacin (disk diffusion or MIC). It is essen-
tial to consider this strain at both national and international
level, in order to take preventive measures as soon as possi-
ble to limit its worldwide propagation. Like this, we suggest
including this emerging Salmonella in the European Union’s list
of target serotypes for mandatory monitoring (EU Commission
regulations No.200/2012 of 8 March 2012).
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